,i #aafth ,,congress #ast ,session ,h4 ,r4 #aebj ,,in ,,the ,,house ,,of ,,representatives ,march #e1 #bjai,ms4 ,eshoo introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,public ,health ,service ,act to provide for the publication of a list of licensed biological products1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,purple ,book ,continuity ,act of #bjai4 #b4 ,public ,listing ,section #cea7k7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77 is amended by adding at the end the following3 7#i7 ,public listing 7,a7 ,in general 7i7 ,initial publication ,not later than #fj days after the date of enactment of the ,purple ,book ,continuity ,act of #bjai1 the ,secretary shall publish and make available to the public electronically-- 7,i7 a list in alphabetical order of the official and proprietary name of each biological product for which a biologics license under subsection 7a7 or this subsection is in effect as of such date of enactment2 7,,ii7 the date of licensing if the biological product is licensed after #aiha and the number of the application which was approved2 and 7,,iii7 whether in vitro or in vivo bioequivalence studies1 or both such studies1 are required for applications filed under this subsection which will refer to the biological product published4 7ii7 ,revisions ,every #cj days after the publication of the first list under clause 7i71 the ,secretary shall revise the list to include each biological product which has been licensed under subsection 7a7 or this subsection during the #cj-;day period4 7iii7 ,patent information ,when patent information has been provided by the reference product sponsor to the subsection 7k7 applicant respecting a biological product included on the list published under this subparagraph1 the ,secretary shall1 in revisions made under clause 7ii71 include such information for such biological product4 7,b7 ,date of publication ,a biological product for which a license is in effect under subsection 7a7 or this subsection shall1 for purposes of this subsection1 be considered to have been published under subparagraph 7,a7 on the later of-- 7i7 the date of its licensing2 or 7ii7 the date of its publication in the list that-- 7,i7 was published under this section before the initial publication of the list under subparagraph 7,a72 and 7,,ii7 was equivalent to the list published under section #eje7;j77#g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act and comprised of patents associated with applications filed under subsection 7a7 of this section or under this subsection4 7,c7 ,withdrawal or suspension of licensure ,if the licensing of a biological product was withdrawn or suspended for safety1 purity1 or potency reasons1 it may not be published in the list under subparagraph 7,a74 ,if the withdrawal or suspension occurred after its publication in such list-- 7i7 it shall be immediately removed from such list-- 7,i7 for the same period as the withdrawal or suspension2 or 7,,ii7 if the listed drug has been withdrawn from sale1 for the period of withdrawal from sale or1 if earlier1 the period ending on the date the ,secretary determines that the withdrawal from sale is not for safety1 purity1 or potency reasons2 and 7ii7 a notice of the removal shall be published in the ,federal ,register4 4 #c4 ,review and report on types of biological product patents ,to be listed ,not later than #c years after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall-- 7#a7 complete a review of1 and formulate recommendations on1 the types of biological product patents that should be included in or removed from the list required by paragraph 7#i7 of section #cea7k7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k771 as added by section #b2 and 7#b7 report such recommendations to the ,congress4